意大利罕见胆道癌症倡议(IRaBiCa):由 Gruppo Oncologico dell'Italia Meridionale (GOIM) 与 Gruppo Italiano Colangiocarcinoma (GICO) 合作开展的一项多中心观察研究。

IF 2 4区 医学 Q3 ONCOLOGY Tumori Pub Date : 2024-06-01 Epub Date: 2024-02-07 DOI:10.1177/03008916231222761
Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris
{"title":"意大利罕见胆道癌症倡议(IRaBiCa):由 Gruppo Oncologico dell'Italia Meridionale (GOIM) 与 Gruppo Italiano Colangiocarcinoma (GICO) 合作开展的一项多中心观察研究。","authors":"Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris","doi":"10.1177/03008916231222761","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.</p><p><strong>Methods: </strong>An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.</p><p><strong>Conclusions: </strong>We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"203-208"},"PeriodicalIF":2.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).\",\"authors\":\"Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris\",\"doi\":\"10.1177/03008916231222761\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.</p><p><strong>Methods: </strong>An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.</p><p><strong>Conclusions: </strong>We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.</p>\",\"PeriodicalId\":23349,\"journal\":{\"name\":\"Tumori\",\"volume\":\" \",\"pages\":\"203-208\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tumori\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03008916231222761\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916231222761","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言约 90% 的胆管癌是腺癌,具有腺状或管状结构,内衬上皮细胞,不产生胆汁,分化程度不一,发生在脱鳞基质的背景下。其余 10%的肿瘤属于较罕见的组织学变异,人们对其生物学行为、分子特征以及对各种可能疗法(包括分子疗法)的敏感性知之甚少。由于这些罕见肿瘤被排除在临床试验之外,因此仅在病例报告或小型回顾性系列研究中有所描述。因此,我们将收集一系列有治疗和随访数据的罕见胆道组织类型/变异的流行病学、病理学和临床特征:方法:意大利成立了一个胆道罕见肿瘤工作组(IRaBiCa),该工作组发起了一项多中心回顾性研究,涉及 34 个意大利癌症中心。连续变量将以中位数±标准差表示,而分类变量将以频率表示。卡普兰-迈尔(Kaplan-Maier)分析法将用于比较不同组织类型的无病生存期、无进展生存期和总生存期:我们希望能收集到有关胆道癌罕见组织型的新数据,这些数据将有助于支持胆道癌的分子和免疫学特征描述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).

Introduction: About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.

Methods: An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.

Conclusions: We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Tumori
Tumori 医学-肿瘤学
CiteScore
3.50
自引率
0.00%
发文量
58
审稿时长
6 months
期刊介绍: Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.
期刊最新文献
Clinical difference between solitary and multiple pulmonary adenocarcinoma nodules. MLH1 promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of MLH1 gene? Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis. Factors influencing the colorectal surveillance adherence in Lynch Syndrome: A retrospective monocentric study. Implications and mechanisms of O-GlcNAcylation in cancer therapy resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1